Role of β2‐glycoprotein I in the pathogenesis of the antiphospholipid syndrome
Rheumatology & Autoimmunity, 2023 Antiphospholipid syndrome (APS) is typically characterized by increased levels of three classes of antiphospholipid antibodies, namely lupus anticoagulant, anti‐β2‐glycoprotein I (anti‐β2GPI), and anticardiolipin antibodies.
Jing Li, Xiangrui Zhu, Juan Feng
doaj +2 more sources
Optimization of Unnicked β2-Glycoprotein I and High Avidity Anti-β2-Glycoprotein I Antibodies Isolation [PDF]
Journal of Immunology Research, 2014 Patient biological material for isolation of β2-glycoprotein I (β2GPI) and high avidity IgG anti-β2-glycoprotein I antibodies (HAv anti-β2GPI) dictates its full utilization.
Andrej Artenjak +6 more
doaj +2 more sources
β2-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase. [PDF]
PLoS ONE, 2016 Angiogenesis is the process of new blood vessel formation, and it plays a key role in various physiological and pathological conditions. The β2-glycoprotein I (β2-GPI) is a plasma glycoprotein with multiple biological functions, some of which remain to ...
Wen-Chin Chiu +3 more
doaj +2 more sources
Tolerogenic β2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome. [PDF]
PLoS ONE, 2018 DNA vaccines have recently emerged as a therapeutic agent for treating autoimmune diseases, such as multiple sclerosis. Antiphospholipid antibody syndrome (APS) is an autoimmune disease characterized by β2-glycoprotein I (β2-GPI)-targeting ...
Ya-Hsuan Chao +4 more
doaj +3 more sources
Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus [PDF]
Научно-практическая ревматология, 2022 The study of antiphospholipid antibodies (aPL), not included in the Sydney diagnostic criteria, in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) is poorly understood.The aim of this study – to determine the clinical significance ...
F. A. Cheldieva +5 more
doaj +2 more sources
Interference in point-of-care international normalized ratio monitoring in patients with lupus anticoagulant is correlated with anti-β2-glycoprotein I antibody titers. [PDF]
Res Pract Thromb Haemost, 2023 Background: Patients with antiphospholipid syndrome (APS) receive anticoagulant therapy with vitamin K antagonists (VKAs) to prevent recurrent thrombosis. VKA treatment requires strict monitoring with an international normalized ratio (INR).
Noordermeer T +7 more
europepmc +2 more sources
The certification of the concentration of anti-β2-glycoprotein I IgG in human serum: ERM®-DA477/IFCC [PDF]
, 2022 This report describes the production of ERM-DA477/IFCC, which is a matrix material certified for the concentration of anti-β2 glycoprotein I IgG (anti-β2GPI IgG) in human serum.
MARTOS Gustavo +4 more
core +1 more source
Gastrointestinal symptoms as the first manifestation of antiphospholipid syndrome
BMC Gastroenterology, 2021 Background Antiphospholipid syndrome (APS) is an acquired pre-thrombotic autoimmune condition, which produces autoantibodies called antiphospholipid antibodies (APL) against phospholipid-binding plasma proteins. The diagnosis of APS requires at least one
Xiaojuan Zou +5 more
doaj +1 more source
Risk factors and recurrent thrombosis in primary antiphospholipid syndrome
Exploration of Immunology, 2023 Aim: The study aims to evaluate the incidence of recurrent thromboses in patients with primary antiphospholipid syndrome (PAPS) and its association with the presence of different antiphospholipid antibodies (aPLs) and known thrombogenic risk factors ...
Fariza A. Cheldieva +6 more
doaj +1 more source
Advances in Rheumatology, 2021 Objectives To explore the risk factors for systemic lupus erythematosus (SLE) flare and their impact on prognosis. Methods The clinical characteristics, laboratory results, and treatment plans of 121 patients with SLE flare were retrospectively analyzed.
Xiaohong Zeng +6 more
doaj +1 more source